2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
2
Insulin Resistance
2
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Ketosis
1
Glioma
1
Glioblastoma
1
Diabetes Mellitus, Type 2
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Docetaxel
292
Prednisone
240
enzalutamide
193
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
169
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
92
gallium 68 PSMA-11
81
abiraterone
81
Specimen Handling
73
darolutamide
65
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
52
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Biguanides
×
Clear all
NCT02497638
2021-04-19
LIGAND
University Health Network, Toronto
Phase 2
Withdrawn